NEWS

  • All
  • Corporate News
  • Media
All
  • All
  • Corporate News
  • Media
Corporate News

Mainz Biomed Completes Successful Pre-Submission Process with the U.S. FDA for ColoAlert’s Pivotal Clinical Trial

Read More
Corporate News

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

Read More
Corporate News

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

Read More
Corporate News

Mainz Biomed Announces Year End 2021 Results

Read More
Corporate News

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

Read More
Corporate News

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

Read More